FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891956703> ?p ?o ?g. }

• W2891956703 abstract "e18051 Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes of advanced renal cell carcinoma (RCC) patients, although complete remission is uncommon. Disease-specific survival in RCC varies by race/ethnicity, but race is not an independent predictor of survival within single-payer healthcare systems, pointing to the importance of access to treatment. We analyzed patient-level utilization of three TKIs (sunitinib, sorafenib, and pazopanib) among veterans with RCC. Methods: In this retrospective cohort study, we used data from Department of Veterans Affairs (VA) Corporate Data Warehouse to identify veterans diagnosed with RCC from 2006 to 2015 and exposed to TKIs, and to obtain their demographic and clinical information. The distribution of patients’ characteristics across treatments was evaluated using chi square and t-tests. Results: Of 2,410 patients exposed to TKIs, 956 (40%) received more than one TKI. Sunitinib was prescribed to 1,761 (73%) patients, pazopanib to 766 (32%), and sorafenib to 600 (25%) patients. The use of sorafenib declined steadily over time, from 37% of patients diagnosed in 2006 to 2% of those diagnosed in 2015, while the use of pazopanib grew from 8% to 38%, respectively. The comparison group were unexposed patients in Stage IV RCC (N = 1,144). Patients exposed to targeted treatments were significantly younger at diagnosis than those with no exposure (mean [M] age 65 years, SD 9 vs. m = 70 years, SD 10; p < 001). There were no statistically significant racial/ethnic or gender differences between patients exposed and unexposed to TKIs. Exposed patients had significantly higher body mass index (BMI) than unexposed (M = 29.6, SD 6 vs m = 27.9, SD 6, respectively; p < 0.01). Receipt of TKI was positively correlated with both surgery and chemotherapy, and negatively correlated with Charlson comorbidity index (p < 0.01). Conclusions: We documented equal access to TKIs treatment within the VA among RCC patients of different ethnic backgrounds and gender. Treatment with TKIs was correlated with younger age and fewer comorbidities, but higher BMI. We observed trends in use of individual TKIs, with more recently approved pazopanib gradually replacing sorafenib and sunitinib." @default.
• W2891956703 created "2018-09-27" @default.
• W2891956703 creator A5004245154 @default.
• W2891956703 creator A5030877878 @default.
• W2891956703 creator A5037435182 @default.
• W2891956703 creator A5042655948 @default.
• W2891956703 creator A5048214696 @default.
• W2891956703 creator A5065027113 @default.
• W2891956703 creator A5067620656 @default.
• W2891956703 creator A5075594049 @default.
• W2891956703 creator A5077005871 @default.
• W2891956703 date "2017-05-20" @default.
• W2891956703 modified "2023-09-22" @default.
• W2891956703 title "Equity in access to tyrosine kinase inhibitors among veterans diagnosed with renal cell carcinoma." @default.
• W2891956703 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18051" @default.
• W2891956703 hasPublicationYear "2017" @default.
• W2891956703 type Work @default.
• W2891956703 sameAs 2891956703 @default.
• W2891956703 citedByCount "0" @default.
• W2891956703 crossrefType "journal-article" @default.
• W2891956703 hasAuthorship W2891956703A5004245154 @default.
• W2891956703 hasAuthorship W2891956703A5030877878 @default.
• W2891956703 hasAuthorship W2891956703A5037435182 @default.
• W2891956703 hasAuthorship W2891956703A5042655948 @default.
• W2891956703 hasAuthorship W2891956703A5048214696 @default.
• W2891956703 hasAuthorship W2891956703A5065027113 @default.
• W2891956703 hasAuthorship W2891956703A5067620656 @default.
• W2891956703 hasAuthorship W2891956703A5075594049 @default.
• W2891956703 hasAuthorship W2891956703A5077005871 @default.
• W2891956703 hasConcept C126322002 @default.
• W2891956703 hasConcept C143998085 @default.
• W2891956703 hasConcept C170493617 @default.
• W2891956703 hasConcept C17744445 @default.
• W2891956703 hasConcept C199539241 @default.
• W2891956703 hasConcept C199728807 @default.
• W2891956703 hasConcept C2777472916 @default.
• W2891956703 hasConcept C42362537 @default.
• W2891956703 hasConcept C502942594 @default.
• W2891956703 hasConcept C71924100 @default.
• W2891956703 hasConceptScore W2891956703C126322002 @default.
• W2891956703 hasConceptScore W2891956703C143998085 @default.
• W2891956703 hasConceptScore W2891956703C170493617 @default.
• W2891956703 hasConceptScore W2891956703C17744445 @default.
• W2891956703 hasConceptScore W2891956703C199539241 @default.
• W2891956703 hasConceptScore W2891956703C199728807 @default.
• W2891956703 hasConceptScore W2891956703C2777472916 @default.
• W2891956703 hasConceptScore W2891956703C42362537 @default.
• W2891956703 hasConceptScore W2891956703C502942594 @default.
• W2891956703 hasConceptScore W2891956703C71924100 @default.
• W2891956703 hasLocation W28919567031 @default.
• W2891956703 hasOpenAccess W2891956703 @default.
• W2891956703 hasPrimaryLocation W28919567031 @default.
• W2891956703 hasRelatedWork W1993326728 @default.
• W2891956703 hasRelatedWork W1993527100 @default.
• W2891956703 hasRelatedWork W2243935214 @default.
• W2891956703 hasRelatedWork W2276893811 @default.
• W2891956703 hasRelatedWork W2586942420 @default.
• W2891956703 hasRelatedWork W2587686362 @default.
• W2891956703 hasRelatedWork W2590105029 @default.
• W2891956703 hasRelatedWork W2590153352 @default.
• W2891956703 hasRelatedWork W2600518406 @default.
• W2891956703 hasRelatedWork W2617691504 @default.
• W2891956703 hasRelatedWork W2906596195 @default.
• W2891956703 hasRelatedWork W2907463862 @default.
• W2891956703 hasRelatedWork W2908272576 @default.
• W2891956703 hasRelatedWork W2922260783 @default.
• W2891956703 hasRelatedWork W2940100935 @default.
• W2891956703 hasRelatedWork W3008706748 @default.
• W2891956703 hasRelatedWork W302913295 @default.
• W2891956703 hasRelatedWork W3092031158 @default.
• W2891956703 hasRelatedWork W3109483758 @default.
• W2891956703 hasRelatedWork W3134042901 @default.
• W2891956703 isParatext "false" @default.
• W2891956703 isRetracted "false" @default.
• W2891956703 magId "2891956703" @default.
• W2891956703 workType "article" @default.